高龄老年肺部感染应用胸腺肽α1的免疫调节疗效  

Immune Regulation Effect on Advanced Age Lung Infection Patients with Thymosin Alpha 1

作　　者：赵晟珣[1] 王桦[1] 杨帆[1] 王家瑜[1] 张艳芳[1] 葛亮[1] 吴晓玲[1] 

机构地区：[1]武汉大学中南医院综合医疗科,湖北武汉430071

出　　处：《武汉大学学报（医学版）》2014年第3期407-409,共3页Medical Journal of Wuhan University

基　　金：湖北省科技攻关计划项目(编号:2005AA401D26)

摘　　要：目的:探讨胸腺肽α1(Tα1)免疫调节辅助治疗高龄老年肺部感染的临床作用,观察评估细胞免疫功能T淋巴细胞亚群(CD3+、CD3+CD4+、CD3+CD8+、CD4+/CD8+)指标动态变化与临床疗效。方法:入选≥80岁高龄老年肺炎患者70例,随机分为治疗组(Tα1组)和对照组,每组各35例。Tα1组使用基础治疗(抗感染、袪痰、平喘、对症治疗)+Tα1注射液1mg,皮下注射,1次/d,2周为一个疗程。对照组35例仅使用基础治疗。两组治疗前后对比观察外周血T淋巴细胞亚群(CD3+、CD3+CD4+、CD3+CD8+、CD4+/CD8+)免疫指标及临床疗效。结果:疗程结束后结果显示,Tα1组各项免疫指标明显改善提高,优于对照组(P<0.05)。临床疗效观察总有效率Tα1组94.3%;高于对照组82.6%,两组比较有统计学差异(P<0.05)。结论:Tα1辅助治疗高龄老年肺部感染可有效调节增强细胞免疫功能,促进肺部炎症吸收,改善预后。Objective： To analyze the values of thymosin al（Tal） in regulating immune function in adju- vant treatment of aged patients with lung infection, and to evaluate the dynamic changes of T lymphocyte subsets indices （CD3＋ CD3＋ CD4＋ CD3＋ CDS＋and CD4＋/CD8＋） and clinical effect. Methods： Seventy advanced age patients （≥80 years） with pneumonia, were randomly divided in- to Tal treatment group and control group, with 35 cases in each group. The peripheral blood T lymphocyte subsets （CD3＋, CD4＋ CD8＋ and CD4＋/CD8＋） as well as clinical efficacy were com- pared between the two groups. Results： After the treatment, the T lymphocyte subsets counts in Tal group improved more significantly than in control group （all P〈0.05）. The total effective rate was respectively 94.3% in Tal group and 82.6% in control group, with significant difference （P〈0.05）. Conclusion： Thymosin al can effectively regulate immune function in adjuvant treatment of aged patients with lung infection, promote the absorption of pulmonary inflammation, and improve general condition of the patients.

关 键 词：高龄老人 肺部感染 胸腺肽Α1 免疫调节 

分 类 号：R563.1[医药卫生—呼吸系统]